Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-02-23
1998-06-16
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546194, A01N 4340
Patent
active
057671311
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
Benign Prostatic Hyperplasia (BPH), also called Benign Prostatic Hypertrophy, is a progressive condition which is characterized by a nodular enlargement of prostatic tissue resulting in obstruction of the urethra. This results in increased frequency of urination, nocturia, a poor urine stream and hesitancy or delay in starting the urine flow. Chronic consequences of BPH can include hypertrophy of bladder smooth muscle, a decompensated bladder and an increased incidence of urinary tract infection. The specific biochemical, histological and pharmacological properties of the prostate adenoma leading to the bladder outlet obstruction are not yet known. However, the development of BPH is considered to be an inescapable phenomenon for the aging male population. BPH is observed in approximately 70% of males over the age of 70. Currently, in the United States, the method of choice for treating BPH is surgery (Lepor, H., Urol. Clinics North Amer., 17, 651 (1990)). Over 400,000 prostatectomies are performed annually (data from 1986). A medicinal alternative to surgery is clearly very desirable. The limitations of surgery for treating BPH include the morbidity rate of an operative procedure in elderly men, persistence or recurrence of obstructive and irritative symptoms, as well as the significant cost of surgery.
.alpha.-Adrenergic receptors are specific neuroreceptor proteins located in the peripheral and central nervous systems on tissues throughout the body. These receptors are important switches for controlling many physiological functions and, thus, represent important targets for drug development. In fact, many .alpha.-adrenergic drugs have been developed over the past 40 years. Examples include clonidine, phenoxybenzamine and prazosin (treatment of hypertension), naphazoline (nasal decongestant), and apraclonidine (treating glaucoma). .alpha.-Adrenergic drugs can be broken down into two distinct classes: agonists (clonidine and naphazoline are agonists), which mimic the receptor activation properties of the endogenous neurotransmitter norepinephrine, and antagonists (phenoxybenzamine and prazosin are antagonists), which act to block the effects of norepinephrine. Many of these drugs are effective but also produce unwanted side effects (for example, clonidine produces dry mouth and sedation in addition to its antihypertensive effects).
During the past 15 years a more precise understanding of .alpha.-adrenergic receptors and their drugs has evolved through increased scientific scrutiny. Prior to 1977, only one .alpha.-adrenergic receptor was known to exist. Between 1977 and 1988, it was accepted by the scientific community that at least two .alpha.-adrenergic receptors--.alpha..sub.1 and .alpha..sub.2 --existed in the central and peripheral nervous systems. Since 1988, new techniques in molecular biology have led to the identification of at least six .alpha.-adrenergic receptors which exist throughout the central and peripheral nervous systems: .alpha..sub.1A, .alpha..sub.1B, .alpha..sub.1C, .alpha..sub.2A, .alpha..sub.2B and .alpha..sub.2C (Bylund, D. B., FASEB J., 6, 832 (1992)). It is not known precisely which physiological responses in the body are controlled by each of these receptors. In addition, many .alpha.-adrenergic drugs that were developed before 1992 are not selective for any particular .alpha.-adrenergic receptor. Many of these drugs produce untoward side effects which may be attributed to their poor .alpha.-adrenergic receptor selectivity.
Since the mid 1970's, nonselective .alpha.-antagonists have been prescribed to treat BPH. In 1976, M. Caine, et al. (Brit. J. Urol., 48, 255 (1976)), reported that the nonselective .alpha.-antagonist phenoxybenzamine was useful in relieving the symptoms of BPH. This drug may produce its effects by interacting with .alpha.-receptors located on the prostate. However, this drug also produces significant side effects which severely limit its use in treating patients on a chronic basis. More recently, the .alpha.-adrenergic antagonists
REFERENCES:
patent: 4652573 (1987-03-01), Minaskanian et al.
patent: 4707486 (1987-11-01), Flockerzi et al.
patent: 4853393 (1989-08-01), Zimmerman et al.
patent: 4895846 (1990-01-01), Poindexter et al.
patent: 4937242 (1990-06-01), Matsui et al.
patent: 4975440 (1990-12-01), Flockerzi et al.
patent: 4994461 (1991-02-01), Ulrich
patent: 5017586 (1991-05-01), Schlager
patent: 5158963 (1992-10-01), Nakanishi et al.
patent: 5326772 (1994-07-01), Klemm et al.
patent: 5403847 (1995-04-01), Gluchowski et al.
Murray, D.L. et al, J. Ocular Pharmacol. spring 1985, 1(1), pp. 3-18, online results relied upon.
Lepor, H. Prostate Suppl. 1990, 3, pp. 75-84.
Isaacs, J.T., "Importance of the Natural History of Benign Prostatic Hyperplasia In The Evaluation of Pharmacologic Intervention" The Prostrate (1990), Supplement 3, pp. 1-7 (Exhibit 12).
Hieble, J.P., et al., "In Vitro Characterization of the .alpha.-Adrenoceptors in Human Prostate," European Journal of Pharmacology, 107: 111-117 (1985), The Netherlands (Exhibit 13).
Archibald, J.L., et al., "Antihypertensive Ureidopiperidines," Journal of Medical Chemistry, (1980) 23: 857-861.
Boer, R., et al., "(+)-Niguldipine Binds With Very High Affinity to Ca.sup.2+ Channels and to a Subtype of .alpha..sup.1 -Adrenoreceptors," European Journal of Pharmacology--Molecular Pharmacology Section 172: 131-145 (1989), The Netherlands.
Yamada, S., et al., "Alpha-1 Adrenoceptors in Human Prostate: Characterization and Alteration in Benign Prostatic Hypertrophy," Journal of Pharmacology and Experimental Therapeutics, 242: 326-330 (1987).
Chiu George
Gluchowski Charles
Marzabadi Mohammed R.
Nagarathnam Dhanapalan
Wetzel John M.
Dahlen Garth M.
Ivy C. Warren
Synaptic Pharmaceutical Corporation
White John P.
LandOfFree
Dihydropyridines and new uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dihydropyridines and new uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydropyridines and new uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1726357